|
JP2008507288A
(ja)
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
ES2649983T3
(es)
|
2005-11-23 |
2018-01-16 |
Acceleron Pharma, Inc. |
Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
US20090176885A1
(en)
*
|
2006-02-02 |
2009-07-09 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
MX2009008222A
(es)
|
2007-02-01 |
2009-10-12 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
|
|
TW201803890A
(zh)
|
2007-02-02 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
EA018221B1
(ru)
|
2007-02-09 |
2013-06-28 |
Акселерон Фарма Инк. |
АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CN101861161B
(zh)
|
2007-09-18 |
2017-04-19 |
阿塞勒隆制药公司 |
活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
|
|
EP2240024A4
(en)
*
|
2008-01-15 |
2014-05-21 |
Wellstat Therapeutics Corp |
COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
TW201803586A
(zh)
|
2008-08-14 |
2018-02-01 |
艾瑟勒朗法瑪公司 |
使用ｇｄｆ阱以增加紅血球水平
|
|
KR20120049214A
(ko)
|
2009-06-08 |
2012-05-16 |
악셀레론 파마 인코포레이티드 |
발열성 지방세포를 증가시키는 방법
|
|
KR20180026795A
(ko)
|
2009-06-12 |
2018-03-13 |
악셀레론 파마 인코포레이티드 |
절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
|
|
AU2010315245B2
(en)
*
|
2009-11-03 |
2016-11-03 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
EP3332796A1
(en)
|
2009-11-17 |
2018-06-13 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
AU2011326586A1
(en)
|
2010-11-08 |
2013-05-30 |
Acceleron Pharma, Inc. |
ActRIIA binding agents and uses thereof
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8500260B2
(en)
|
2011-04-27 |
2013-08-06 |
Xerox Corporation |
Ink compositions incorporating substituted oxazoline compounds or substituted oxazoline derivatives
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US10195249B2
(en)
|
2012-11-02 |
2019-02-05 |
Celgene Corporation |
Activin-ActRII antagonists and uses for treating bone and other disorders
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
JP2018501307A
(ja)
|
2014-12-03 |
2018-01-18 |
セルジーン コーポレイション |
アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
|